Trial Profile
Phase I Study of the Combination of Midostaurin, Bortezomib, and Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Midostaurin (Primary) ; Cytarabine; Etoposide; Mitoxantrone
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 04 Jul 2016 Status changed from active, no longer recruiting to completed.
- 14 Oct 2014 Planned End Date changed from 1 Aug 2014 to 1 Dec 2014 according to ClinicalTrials.gov record.
- 14 Oct 2014 Planned primary completion date changed from 1 Aug 2014 to 1 Dec 2014 according to ClinicalTrials.gov record.